Gilead Sciences Shows Strong Growth Driven by HIV and Liver Disease Portfolios
Gilead Sciences (GILD) reported a strong third quarter, with total revenue increasing 7% year-over-year to $8.3 billion. Despite significant declines in COVID-19 medicine sales (Veklury) and cell therapy, the company's core HIV franchise saw an 18% increase in sales, reaching $6.2 billion. This growth was primarily driven by Biktarvy and Descovy. The company also reported a 13% rise in its liver disease portfolio revenue. Recent regulatory approvals for products such as Bixlenvo, Hepcludex, and label expansions for Trodelvy are expected to bolster medium-term financial results. While oncology remains a secondary focus with mixed historical success, Gilead's extensive oncology pipeline offers potential for future diversification beyond its dominant HIV business.